Measurement of Plasma Cell-Free Mitochondrial Tumor DNA Improves Detection of Glioblastoma in Patient-Derived Orthotopic Xenograft Models.
View / Open Files
Authors
Mair, Richard
Mouliere, Florent
Smith, Christopher G
Gale, Davina
Tsui, Dana WY
Watts, Colin
Rosenfeld, Nitzan
Brindle, Kevin M
Publication Date
2019-01-01Journal Title
Cancer Res
ISSN
0008-5472
Publisher
American Association for Cancer Research (AACR)
Volume
79
Issue
1
Pages
220-230
Language
eng
Type
Article
This Version
AM
Physical Medium
Print-Electronic
Metadata
Show full item recordCitation
Mair, R., Mouliere, F., Smith, C. G., Chandrananda, D., Gale, D., Marass, F., Tsui, D. W., et al. (2019). Measurement of Plasma Cell-Free Mitochondrial Tumor DNA Improves Detection of Glioblastoma in Patient-Derived Orthotopic Xenograft Models.. Cancer Res, 79 (1), 220-230. https://doi.org/10.1158/0008-5472.CAN-18-0074
Abstract
The factors responsible for the low detection rate of cell-free tumor DNA (ctDNA) in the plasma of patients with glioblastoma (GBM) are currently unknown. In this study, we measured circulating nucleic acids in patient-derived orthotopically implanted xenograft (PDOX) models of GBM (n = 64) and show that tumor size and cell proliferation, but not the integrity of the blood-brain barrier or cell death, affect the release of ctDNA in treatment-naïve GBM PDOX. Analysis of fragment length profiles by shallow genome-wide sequencing (<0.2× coverage) of host (rat) and tumor (human) circulating DNA identified a peak at 145 bp in the human DNA fragments, indicating a difference in the origin or processing of the ctDNA. The concentration of ctDNA correlated with cell death only after treatment with temozolomide and radiotherapy. Digital PCR detection of plasma tumor mitochondrial DNA (tmtDNA), an alternative to detection of nuclear ctDNA, improved plasma DNA detection rate (82% vs. 24%) and allowed detection in cerebrospinal fluid and urine. Mitochondrial mutations are prevalent across all cancers and can be detected with high sensitivity, at low cost, and without prior knowledge of tumor mutations via capture-panel sequencing. Coupled with the observation that mitochondrial copy number increases in glioma, these data suggest analyzing tmtDNA as a more sensitive method to detect and monitor tumor burden in cancer, specifically in GBM, where current methods have largely failed. SIGNIFICANCE: These findings show that detection of tumor mitochondrial DNA is more sensitive than circulating tumor DNA analysis to detect and monitor tumor burden in patient-derived orthotopic xenografts of glioblastoma.
Keywords
Animals, Biomarkers, Tumor, Body Fluids, Circulating Tumor DNA, DNA, Mitochondrial, DNA, Neoplasm, Female, Glioblastoma, High-Throughput Nucleotide Sequencing, Humans, Mitochondria, Rats, Rats, Nude, Tumor Cells, Cultured, Xenograft Model Antitumor Assays
Sponsorship
N. Rosenfeld and K. Brindle are supported by the University of Cambridge, Cancer Research UK (grant numbers A11906, A20240, 17242, 16465) and Hutchison Whampoa Limited. N. Rosenfeld has received funding from the European Research Council under the European Union's Seventh Framework Programme (FP/2007-2013) / ERC Grant Agreement n. 337905. C. Watts is supported by The Brain Tumour Charity grant 10/136.
Funder references
Cancer Research Uk (None)
Cancer Research UK (C48525/A18345)
Addenbrooke's Charitable Trust (ACT) (unknown)
Cancer Research UK (CB4100)
Cancer Research UK (C14303/A17197)
European Research Council (337905)
Cancer Research UK (unknown)
Identifiers
External DOI: https://doi.org/10.1158/0008-5472.CAN-18-0074
This record's URL: https://www.repository.cam.ac.uk/handle/1810/286401
Rights
Licence:
http://www.rioxx.net/licenses/all-rights-reserved
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk